Home/Pipeline/Investigational drugs for Mycetoma

Investigational drugs for Mycetoma

Mycetoma

Pre-clinicalActive development

Key Facts

Indication
Mycetoma
Phase
Pre-clinical
Status
Active development
Company

About Eisai

Eisai is a Japanese pharmaceutical giant with a strong commitment to human health care (hhc), focusing on addressing unmet medical needs in neurology, oncology, and neglected tropical diseases. The company has achieved significant breakthroughs in Alzheimer's treatment with Lecanemab and maintains a robust oncology portfolio including multi-targeted kinase inhibitors. Eisai is also deeply committed to global health initiatives, providing treatments for neglected tropical diseases in developing countries while maintaining strong financial performance as a publicly traded company.

View full company profile